Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: UQCR11 (ImmuneEditome ID:10975)

1. Gene summary of enriched editing regions for UQCR11

Gene summary

Gene information	Gene symbol	UQCR11
	Gene ID	10975
	GeneSynonyms	0710008D09Rik\|QCR10\|UQCR
	GeneCytomap	19p13.3
	GeneType	protein-coding
	GeneDescription	cytochrome b-c1 complex subunit 10\|complex III subunit 10\|complex III subunit XI\|ubiquinol-cytochrome c reductase complex 6.4 kDa protein\|ubiquinol-cytochrome c reductase, 6.4kDa subunit
	GeneModificationdate	20230329
	UniprotID	O14957
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:1586549-1590644:-	ENST00000585937.1	ENSG00000267059.2	UQCR11	intronic	AluSx1,AluSq,L1MB7,AluSx3,AluYh3,AluJb,AluJr4,AluJr,L1MB8,AluSq2	chr19:1586549-1590644:-.alignment
chr19:1594674-1597357:-	ENST00000591899.6	ENSG00000127540.10	UQCR11	UTR3	FLAM_C,AluJo,Alu,AluSx,AluJr,MLT1F,L1MC4a,L1MB5,AluSc8,AluSq,AluSp,AluSx1,MLT1B	chr19:1594674-1597357:-.alignment

Top

2. Tumor-specific enriched editing regions for UQCR11

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr19:1586549-1590644:-	BRCA	EER	4.3176e-02
ENSG00000267059.2,UQCR11	BRCA	EAG	2.0123e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr19:1586549-1590644:-	CESC	Cli	EER	1.9707e-02	1.8205e-03	-0.2751
chr19:1586549-1590644:-	KIRC	Path	EER	1.2428e-03	1.2031e-03	0.2141
ENSG00000267059.2,UQCR11	KIRC	Path	EAG	1.2257e-03	9.8447e-03	0.1589
ENSG00000267059.2,UQCR11	LUSC	Path	EAG	2.5458e-03	5.9144e-04	0.1934
chr19:1586549-1590644:-	LUSC	Path	EER	3.5153e-02	8.8480e-03	0.1554

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000127540.10,UQCR11	BLCA	EAG	8.5268e-03	1.8302e-02	8.5278e+06
ENSG00000127540.10,UQCR11	BRCA	EAG	4.4155e-04	1.6223e-02	1.7114e+11
chr19:1586549-1590644:-	KIRC	EER	2.3933e-02	3.5136e-03	2.4448e+02

Top

3. Enriched editing regions and immune related genes for UQCR11

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:1586549-1590644:-

ESCA

EER

ENSG00000256745,RP11-680H20.1

0.3879

6.7066e-04

3.9400e-08

0.4212

GSVA_HALLMARK_MITOTIC_SPINDLE

chr19:1586549-1590644:-

ESCA

EER

ENSG00000132963,POMP

0.3478

3.7343e-03

6.7667e-09

0.4421

AUH;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;HNRNPA1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;RNF219;SLBP;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TROVE2;U2AF2;UPF1;ZC3H7B;AIFM1;DDX3X;ELAVL3;FUS;FXR1;GNL3;GTF2F1;HNRNPL;NONO;NPM1;NUMA1;PCBP2;RBM27;SLTM;TIA1;TNRC6A;U2AF1

POMP

Macrophages_M1

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr19:1586549-1590644:-

ESCA

EER

ENSG00000135211,TMEM60

0.3071

1.5911e-02

1.1424e-07

0.4079

CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LIN28;LIN28A;LIN28B;MOV10;NOP58;PTBP1;RBFOX2;SMNDC1;SND1;SRSF1;TAF15;TROVE2;U2AF2;UPF1;DDX3X;ELAVL3;FUS;FXR1;GNL3;GTF2F1;NUMA1;PCBP2;TIA1;TNRC6A;U2AF1;YTHDF1

T_cells_gamma_delta

GSVA_HALLMARK_DNA_REPAIR

chr19:1586549-1590644:-

ESCA

EER

ENSG00000101608,MYL12A

0.2972

2.1065e-02

2.1917e-12

0.5227

AUH;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM22;RNF219;SBDS;SLBP;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TROVE2;U2AF2;UPF1;ZC3H7B;AIFM1;DDX3X;FUS;FXR1;GNL3;GTF2F1;HNRNPL;NONO;NPM1;NUMA1;PCBP2;RBM27;SLTM;TIA1;TNRC6A;U2AF1;YTHDF1

T_cells_CD8

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:1586549-1590644:-

ESCA

EER

ENSG00000241511,RPS15AP24

0.2937

2.3503e-02

6.3556e-09

0.4428

T_cells_CD8

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

4. Enriched editing regions and immune related splicing for UQCR11

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000267059.2,UQCR11

ESCA

EAG

ENSG00000185252.13

chr22

20394114:20394662:20395332:20395418

-0.3367

3.3085e-03

3.0016e-06

-0.4233

ADAR;AIFM1;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:1586549-1590644:-

ESCA

EER

ENSG00000185252.13

chr22

20394114:20394662:20395332:20395418

-0.3523

1.2344e-03

1.4728e-06

-0.4350

CNBP;CSTF2T;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;RNF219;SBDS;SLBP;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TROVE2;U2AF2;UPF1;AIFM1;DDX3X;FUS;FXR1;GNL3;GTF2F1;HNRNPL;NONO;NUMA1;PCBP2;RBM27;SLTM;TIA1;TNRC6A;U2AF1;YTHDF1

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:1586549-1590644:-

ESCA

EER

ENSG00000205531.8

chr11

2952837:2954410:2954526:2954646

-0.2775

2.5764e-02

2.1839e-06

-0.4152

AUH;CBX7;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;RNF219;SBDS;SLBP;SMNDC1;SND1;SRSF1;TAF15;TARBP2;TARDBP;TROVE2;U2AF2;UPF1;ZC3H7B;AIFM1;DDX3X;ELAVL3;FUS;FXR1;GNL3;GTF2F1;HNRNPL;NONO;NPM1;NUMA1;PCBP2;RBM27;SLTM;TIA1;TNRC6A;U2AF1;YTHDF1

T_cells_CD4_naive

GSVA_HALLMARK_HYPOXIA

ENSG00000267059.2,UQCR11

ESCA

EAG

ENSG00000149532.11

chr11

61419921:61420573:61421191:61421257

-0.2992

1.9995e-02

5.0888e-06

-0.4076

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr19:1586549-1590644:-

ESCA

EER

ENSG00000149532.11

chr11

61419921:61420573:61421191:61421257

-0.3060

1.2516e-02

2.6817e-06

-0.4184

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

ENSG00000267059.2,UQCR11

GBM

EAG

ENSG00000184436.7

chr22

21000646:21000787:21001255:21001411

-0.4118

5.8179e-03

4.6285e-07

-0.4393

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Monocytes

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

ENSG00000267059.2,UQCR11

GBM

EAG

ENSG00000267216.1

chr19

58306034:58306216:58312196:58312462

-0.3940

6.0214e-03

6.6195e-06

-0.4031

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_ADIPOGENESIS

ENSG00000267059.2,UQCR11

GBM

EAG

ENSG00000179029.10

chr17

8173236:8174272:8174519:8174616

-0.3730

1.8625e-02

5.2044e-06

-0.4024

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL14;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

Monocytes

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

ENSG00000267059.2,UQCR11

GBM

EAG

ENSG00000067369.9

chr15

43407208:43407570:43407942:43408088

-0.4254

3.8394e-03

1.3761e-06

-0.4226

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL14;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000267059.2,UQCR11

GBM

EAG

ENSG00000121940.11

chr1

108929507:108934942:108937076:108937418

-0.4686

3.4545e-04

4.6670e-06

-0.4027

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_follicular_helper

GSVA_HALLMARK_APOPTOSIS

More results

Top

5. Enriched editing regions and immune infiltration for UQCR11

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000267059.2,UQCR11	ACC	EAG	Monocytes	1.8172e-02	0.4880
chr19:1586549-1590644:-	BLCA	EER	T_cells_CD4_memory_resting	2.6416e-03	0.2479
ENSG00000267059.2,UQCR11	BLCA	EAG	T_cells_CD4_memory_resting	8.0433e-03	0.2057
chr19:1586549-1590644:-	BRCA	EER	Mast_cells_activated	3.3342e-02	-0.0832
ENSG00000127540.10,UQCR11	BRCA	EAG	B_cells_memory	5.1232e-05	0.3992
ENSG00000267059.2,UQCR11	BRCA	EAG	Dendritic_cells_resting	5.7832e-03	0.1040
chr19:1586549-1590644:-	CESC	EER	Dendritic_cells_activated	4.9686e-02	0.1718
ENSG00000267059.2,UQCR11	CESC	EAG	Macrophages_M2	2.6036e-02	-0.1855
chr19:1586549-1590644:-	COAD	EER	Neutrophils	1.7750e-04	0.3054
ENSG00000267059.2,UQCR11	COAD	EAG	Mast_cells_activated	2.4782e-04	0.2894
ENSG00000267059.2,UQCR11	DLBC	EAG	T_cells_regulatory_(Tregs)	2.9523e-03	0.6293
chr19:1586549-1590644:-	ESCA	EER	T_cells_CD8	1.5515e-03	0.2506
ENSG00000127540.10,UQCR11	ESCA	EAG	Macrophages_M2	2.7015e-02	0.4509
ENSG00000267059.2,UQCR11	ESCA	EAG	T_cells_CD8	1.6095e-03	0.2497
chr19:1586549-1590644:-	GBM	EER	T_cells_follicular_helper	9.4854e-03	-0.2452
ENSG00000267059.2,UQCR11	GBM	EAG	T_cells_gamma_delta	9.6931e-03	0.2343
ENSG00000267059.2,UQCR11	HNSC	EAG	Macrophages_M1	4.8956e-03	0.1887
ENSG00000267059.2,UQCR11	KICH	EAG	Plasma_cells	6.4052e-04	0.4847
ENSG00000267059.2,UQCR11	KIRC	EAG	T_cells_CD4_memory_activated	1.0835e-02	0.1840
chr19:1586549-1590644:-	KIRP	EER	Dendritic_cells_activated	2.1275e-03	0.2861
ENSG00000267059.2,UQCR11	KIRP	EAG	Dendritic_cells_activated	3.4464e-02	0.1705
chr19:1586549-1590644:-	LAML	EER	Macrophages_M1	1.3459e-03	0.2594
ENSG00000267059.2,UQCR11	LAML	EAG	Macrophages_M1	1.0968e-03	0.2640
chr19:1586549-1590644:-	LGG	EER	Macrophages_M0	2.8037e-02	-0.1075
ENSG00000267059.2,UQCR11	LGG	EAG	Dendritic_cells_activated	2.3017e-02	-0.1096
chr19:1586549-1590644:-	LIHC	EER	NK_cells_resting	4.7306e-02	0.2712
ENSG00000127540.10,UQCR11	LIHC	EAG	T_cells_CD8	1.9838e-02	0.4302
ENSG00000267059.2,UQCR11	LIHC	EAG	Neutrophils	3.3709e-02	-0.2363
chr19:1586549-1590644:-	LUAD	EER	B_cells_naive	8.1290e-03	-0.1895
ENSG00000127540.10,UQCR11	LUAD	EAG	Macrophages_M1	1.1561e-03	-0.4897
ENSG00000267059.2,UQCR11	LUAD	EAG	B_cells_naive	2.9780e-02	-0.1449
chr19:1586549-1590644:-	LUSC	EER	Dendritic_cells_activated	1.4939e-02	-0.1446
ENSG00000267059.2,UQCR11	LUSC	EAG	Macrophages_M1	6.3157e-03	0.1543
chr19:1586549-1590644:-	MESO	EER	B_cells_naive	9.9435e-03	0.4131
ENSG00000267059.2,UQCR11	MESO	EAG	B_cells_naive	9.3080e-03	0.4062
chr19:1586549-1590644:-	OV	EER	T_cells_regulatory_(Tregs)	1.1135e-02	0.1778
chr19:1594674-1597357:-	OV	EER	Macrophages_M0	2.6756e-03	0.4239
ENSG00000267059.2,UQCR11	OV	EAG	T_cells_regulatory_(Tregs)	1.4660e-02	0.1659
chr19:1586549-1590644:-	PAAD	EER	NK_cells_activated	7.6914e-03	-0.4430
ENSG00000267059.2,UQCR11	PAAD	EAG	T_cells_CD8	4.7867e-02	0.2812
ENSG00000267059.2,UQCR11	PCPG	EAG	Monocytes	3.2179e-02	0.3130
chr19:1594674-1597357:-	PRAD	EER	T_cells_gamma_delta	3.6043e-02	0.2475
ENSG00000267059.2,UQCR11	PRAD	EAG	T_cells_regulatory_(Tregs)	2.3696e-02	0.1297
chr19:1586549-1590644:-	READ	EER	Plasma_cells	1.0244e-02	0.3435
ENSG00000267059.2,UQCR11	READ	EAG	T_cells_follicular_helper	1.5569e-02	0.3247
chr19:1586549-1590644:-	SARC	EER	Monocytes	2.2335e-02	-0.2272
ENSG00000267059.2,UQCR11	SARC	EAG	Plasma_cells	2.9221e-02	0.1959
chr19:1586549-1590644:-	SKCM	EER	T_cells_CD8	1.4921e-04	0.2344
ENSG00000127540.10,UQCR11	SKCM	EAG	NK_cells_activated	2.3474e-02	0.4059
ENSG00000267059.2,UQCR11	SKCM	EAG	T_cells_CD8	4.1635e-03	0.1678
chr19:1586549-1590644:-	STAD	EER	NK_cells_activated	2.2597e-02	0.1253
chr19:1594674-1597357:-	STAD	EER	NK_cells_resting	4.4970e-03	0.2631
ENSG00000267059.2,UQCR11	STAD	EAG	NK_cells_activated	2.3041e-02	0.1232
chr19:1586549-1590644:-	TGCT	EER	B_cells_memory	9.4790e-06	0.5154
ENSG00000267059.2,UQCR11	TGCT	EAG	B_cells_memory	1.7831e-04	0.4145
chr19:1586549-1590644:-	THCA	EER	NK_cells_resting	7.6388e-07	0.4253
chr19:1594674-1597357:-	THCA	EER	T_cells_CD4_memory_activated	2.0509e-02	-0.2587
ENSG00000267059.2,UQCR11	THCA	EAG	NK_cells_resting	4.8672e-06	0.3332
chr19:1586549-1590644:-	THYM	EER	T_cells_follicular_helper	2.9663e-02	-0.3048
ENSG00000267059.2,UQCR11	THYM	EAG	T_cells_follicular_helper	4.6283e-02	-0.2724
ENSG00000267059.2,UQCR11	UCEC	EAG	T_cells_gamma_delta	1.3868e-02	0.3016
chr19:1586549-1590644:-	UVM	EER	B_cells_naive	4.1610e-02	0.3807

Top

6. Enriched editing regions and immune gene sets for UQCR11

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000267059.2,UQCR11	BLCA	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.1688e-02	0.1959
chr19:1586549-1590644:-	BLCA	GSVA_HALLMARK_P53_PATHWAY	EER	6.0901e-04	0.2813
ENSG00000127540.10,UQCR11	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.2697e-04	-0.3794
chr19:1586549-1590644:-	BRCA	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.4083e-07	0.2001
ENSG00000267059.2,UQCR11	BRCA	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	1.4851e-06	0.1804
chr19:1586549-1590644:-	CESC	GSVA_HALLMARK_G2M_CHECKPOINT	EER	2.4283e-02	-0.1968
ENSG00000267059.2,UQCR11	CESC	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	9.9088e-04	-0.2716
ENSG00000267059.2,UQCR11	COAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	4.0183e-05	-0.3225
chr19:1586549-1590644:-	COAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	2.0592e-04	-0.3026
ENSG00000267059.2,UQCR11	DLBC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	5.8098e-04	-0.7006
chr19:1586549-1590644:-	ESCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	3.2447e-02	0.1708
chr19:1586549-1590644:-	GBM	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	1.0233e-07	0.4794
ENSG00000267059.2,UQCR11	GBM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.1825e-07	0.4591
ENSG00000267059.2,UQCR11	HNSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.5666e-04	0.2436
chr19:1586549-1590644:-	HNSC	GSVA_HALLMARK_E2F_TARGETS	EER	1.2087e-03	-0.2279
ENSG00000267059.2,UQCR11	KICH	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.9880e-03	-0.4282
chr19:1586549-1590644:-	KIRC	GSVA_HALLMARK_DNA_REPAIR	EER	3.7840e-04	0.2760
ENSG00000267059.2,UQCR11	KIRC	GSVA_HALLMARK_DNA_REPAIR	EAG	1.1274e-02	0.1830
ENSG00000267059.2,UQCR11	KIRP	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.1127e-03	-0.2603
ENSG00000267059.2,UQCR11	LAML	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.6238e-03	-0.2552
chr19:1586549-1590644:-	LAML	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.1015e-03	-0.2639
ENSG00000267059.2,UQCR11	LGG	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.7598e-04	0.1799
chr19:1586549-1590644:-	LGG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.9566e-06	0.2212
ENSG00000127540.10,UQCR11	LIHC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	6.0067e-03	-0.4977
chr19:1586549-1590644:-	LIHC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.5174e-02	-0.3289
ENSG00000267059.2,UQCR11	LIHC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	2.4265e-02	-0.2502
ENSG00000127540.10,UQCR11	LUAD	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.7784e-02	-0.3256
chr19:1586549-1590644:-	LUAD	GSVA_HALLMARK_APICAL_SURFACE	EER	2.6179e-02	0.1596
ENSG00000127540.10,UQCR11	LUSC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	9.8833e-03	-0.4427
chr19:1586549-1590644:-	LUSC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.5451e-02	0.1438
chr19:1586549-1590644:-	MESO	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	1.4145e-02	0.3949
ENSG00000267059.2,UQCR11	MESO	GSVA_HALLMARK_MYOGENESIS	EAG	1.0148e-02	0.4019
chr19:1594674-1597357:-	OV	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	8.8598e-04	-0.4643
ENSG00000127540.10,UQCR11	OV	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	1.4944e-03	-0.6008
ENSG00000267059.2,UQCR11	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.6824e-03	-0.1968
chr19:1586549-1590644:-	OV	GSVA_HALLMARK_P53_PATHWAY	EER	3.0332e-04	0.2510
chr19:1586549-1590644:-	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	3.0931e-02	0.3653
ENSG00000267059.2,UQCR11	PCPG	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.4298e-03	-0.4320
chr19:1586549-1590644:-	PCPG	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.3990e-02	0.4238
chr19:1586549-1590644:-	PRAD	GSVA_HALLMARK_MYOGENESIS	EER	1.6397e-02	0.1418
chr19:1594674-1597357:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.2779e-02	-0.2921
ENSG00000267059.2,UQCR11	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.6547e-03	-0.1553
ENSG00000267059.2,UQCR11	READ	GSVA_HALLMARK_APICAL_JUNCTION	EAG	2.7078e-04	-0.4724
chr19:1586549-1590644:-	READ	GSVA_HALLMARK_APICAL_JUNCTION	EER	3.6261e-04	-0.4637
chr19:1586549-1590644:-	SARC	GSVA_HALLMARK_HEME_METABOLISM	EER	4.2350e-03	0.2823
ENSG00000267059.2,UQCR11	SKCM	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	7.0360e-03	-0.1580
chr19:1586549-1590644:-	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.9746e-03	0.1846
ENSG00000127540.10,UQCR11	SKCM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.1658e-02	0.3867
chr19:1594674-1597357:-	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.3334e-02	-0.2302
chr19:1586549-1590644:-	STAD	GSVA_HALLMARK_COAGULATION	EER	5.8187e-03	0.1513
ENSG00000127540.10,UQCR11	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.8303e-04	-0.3950
ENSG00000267059.2,UQCR11	STAD	GSVA_HALLMARK_COAGULATION	EAG	3.4704e-02	0.1146
ENSG00000267059.2,UQCR11	TGCT	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.1284e-02	-0.2873
chr19:1586549-1590644:-	TGCT	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	9.9605e-03	-0.3151
ENSG00000267059.2,UQCR11	THCA	GSVA_HALLMARK_APICAL_SURFACE	EAG	3.2681e-02	-0.1593
chr19:1586549-1590644:-	THCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	5.7166e-03	0.2458
chr19:1594674-1597357:-	THCA	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	2.8892e-03	-0.3289
ENSG00000267059.2,UQCR11	UCEC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	2.3424e-02	0.2788
ENSG00000267059.2,UQCR11	UCS	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.5181e-03	-0.5709

Top

7. Enriched editing regions and drugs for UQCR11

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000267059.2,UQCR11	BLCA	BIRB.0796	EAG	1.2105e-02	0.1949
chr19:1586549-1590644:-	BLCA	BIRB.0796	EER	1.4090e-03	0.2628
ENSG00000267059.2,UQCR11	BRCA	MG.132	EAG	1.0986e-02	-0.0959
ENSG00000127540.10,UQCR11	BRCA	AS601245	EAG	4.3344e-03	0.2872
chr19:1586549-1590644:-	BRCA	MG.132	EER	2.5710e-03	-0.1177
chr19:1586549-1590644:-	CESC	Dasatinib	EER	5.6812e-07	-0.4206
ENSG00000267059.2,UQCR11	CESC	Dasatinib	EAG	2.2263e-05	-0.3466
chr19:1586549-1590644:-	COAD	CCT007093	EER	6.4263e-05	-0.3246
ENSG00000267059.2,UQCR11	COAD	CCT007093	EAG	7.5109e-06	-0.3500
ENSG00000267059.2,UQCR11	DLBC	AG.014699	EAG	6.1382e-03	0.5904
ENSG00000127540.10,UQCR11	ESCA	JNK.Inhibitor.VIII	EAG	7.6767e-03	0.5304
chr19:1586549-1590644:-	ESCA	GDC.0449	EER	2.6254e-03	-0.2393
ENSG00000267059.2,UQCR11	ESCA	BMS.536924	EAG	2.3332e-04	-0.2897
chr19:1586549-1590644:-	GBM	GNF.2	EER	1.7155e-08	-0.5040
ENSG00000267059.2,UQCR11	GBM	GNF.2	EAG	6.9562e-10	-0.5239
chr19:1586549-1590644:-	HNSC	AZD.0530	EER	1.2442e-02	-0.1769
ENSG00000267059.2,UQCR11	HNSC	AZD.0530	EAG	7.9597e-03	-0.1785
ENSG00000267059.2,UQCR11	KICH	BIRB.0796	EAG	2.1849e-03	-0.4405
ENSG00000267059.2,UQCR11	KIRC	JW.7.52.1	EAG	1.5845e-02	-0.1744
chr19:1586549-1590644:-	KIRC	MG.132	EER	1.8355e-02	-0.1851
ENSG00000267059.2,UQCR11	KIRP	Lapatinib	EAG	3.2823e-05	0.3280
chr19:1586549-1590644:-	KIRP	A.770041	EER	1.0160e-02	-0.2409
ENSG00000267059.2,UQCR11	LAML	Bicalutamide	EAG	1.2357e-03	-0.2614
chr19:1586549-1590644:-	LAML	Erlotinib	EER	2.6081e-03	-0.2441
ENSG00000267059.2,UQCR11	LGG	BMS.708163	EAG	5.8039e-05	-0.1926
chr19:1586549-1590644:-	LGG	ABT.888	EER	4.6332e-05	0.1979
ENSG00000267059.2,UQCR11	LIHC	Bosutinib	EAG	3.7039e-04	0.3861
chr19:1586549-1590644:-	LIHC	BAY.61.3606	EER	8.9892e-05	0.5074
ENSG00000127540.10,UQCR11	LIHC	Bosutinib	EAG	1.1860e-03	0.5720
ENSG00000267059.2,UQCR11	LUAD	AZ628	EAG	3.3128e-02	-0.1444
ENSG00000127540.10,UQCR11	LUSC	Embelin	EAG	4.7866e-03	0.4791
ENSG00000267059.2,UQCR11	LUSC	CMK	EAG	4.4622e-02	-0.1138
chr19:1586549-1590644:-	LUSC	AZD7762	EER	2.8258e-02	-0.1304
ENSG00000267059.2,UQCR11	MESO	CEP.701	EAG	1.6317e-02	-0.3776
ENSG00000267059.2,UQCR11	OV	Bryostatin.1	EAG	1.3944e-04	-0.2563
ENSG00000127540.10,UQCR11	OV	KIN001.135	EAG	4.1266e-03	0.5532
chr19:1594674-1597357:-	OV	JW.7.52.1	EER	4.7432e-04	0.4851
chr19:1586549-1590644:-	OV	Axitinib	EER	1.1394e-02	0.1773
chr19:1586549-1590644:-	PAAD	AZD.2281	EER	1.8698e-02	0.3955
ENSG00000267059.2,UQCR11	PAAD	JNK.9L	EAG	3.3571e-02	-0.3012
ENSG00000267059.2,UQCR11	PCPG	BI.2536	EAG	2.8098e-02	-0.3204
ENSG00000267059.2,UQCR11	PRAD	BAY.61.3606	EAG	3.9705e-06	0.2610
chr19:1586549-1590644:-	PRAD	Cytarabine	EER	4.0746e-04	0.2077
chr19:1594674-1597357:-	PRAD	BMS.754807	EER	1.9171e-02	-0.2755
ENSG00000267059.2,UQCR11	READ	Imatinib	EAG	3.7685e-04	0.4626
chr19:1586549-1590644:-	READ	Metformin	EER	5.4545e-04	-0.4512
chr19:1586549-1590644:-	SARC	JW.7.52.1	EER	1.6702e-03	-0.3089
ENSG00000267059.2,UQCR11	SARC	Bortezomib	EAG	2.6363e-03	-0.2678
ENSG00000267059.2,UQCR11	SKCM	CMK	EAG	4.4378e-03	0.1666
chr19:1586549-1590644:-	SKCM	Epothilone.B	EER	4.7920e-03	0.1754
ENSG00000127540.10,UQCR11	SKCM	CMK	EAG	1.6178e-02	0.4285
chr19:1594674-1597357:-	STAD	CCT007093	EER	2.5507e-03	0.2788
ENSG00000267059.2,UQCR11	STAD	Cisplatin	EAG	2.2297e-03	-0.1653
chr19:1586549-1590644:-	STAD	Cisplatin	EER	1.2208e-02	-0.1376
ENSG00000127540.10,UQCR11	STAD	Camptothecin	EAG	1.4244e-02	-0.2650
ENSG00000267059.2,UQCR11	TGCT	BX.795	EAG	9.9883e-03	0.2919
chr19:1586549-1590644:-	TGCT	EHT.1864	EER	1.9807e-03	-0.3740
ENSG00000127540.10,UQCR11	THCA	Cisplatin	EAG	6.4388e-03	-0.5024
chr19:1594674-1597357:-	THCA	AICAR	EER	1.1905e-02	0.2799
ENSG00000267059.2,UQCR11	THYM	JNK.Inhibitor.VIII	EAG	4.5409e-03	0.3805
ENSG00000267059.2,UQCR11	UCEC	GDC.0449	EAG	4.9943e-03	-0.3416
ENSG00000267059.2,UQCR11	UCS	Bortezomib	EAG	2.5916e-02	-0.4738
chr19:1586549-1590644:-	UVM	DMOG	EER	4.2243e-02	-0.3796

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType